The Top 5 Biosimilar Articles for the Week of December 13

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of December 13, 2021.

Number 5: Tot Biopharm received China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for an Innovation and Collaboration Center.

Number 4: In midterm results for a phase 2 study presented at the the 2021 San Antonio Breast Cancer Symposium (SABCS), a trastuzumab biosimilar in conjunction with gedatolisib demonstrated an overall response rate of 58.8% with manageable toxicity in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (mBC).

Number 3: Researchers who surveyed patients and oncologists about biosimilars and switches to biosimilars from reference products found discrepancies between patients’ perceptions and physician perceptions of whether the information provided was adequate.

Number 2: Ahead of sales and revenues, Icelandic company Alvotech lined up a massive capital investment and an initial public offering (IPO).

Number 1: Long-term survival findings for the trastuzumab biosimilar Ontruzant demonstrated equivalence to the reference product (Herceptin) in a phase 3 study of patients with HER2–positive breast cancer, investigators reported at the 2021 SABCS.

To read all of these articles and more, visit centerforbiosimilars.com.